Nature Medicine

Published by: Nature Publishing Group  

People

  1. Levine
    Levine
  2. Berger
    Berger
  3. Abdel-Wahab
    Abdel-Wahab
  4. De Stanchina
    De Stanchina
  5. Ladanyi
    Ladanyi
  6. Yaeger
    Yaeger
  7. Massague
    Massague
  8. Perales
    Perales
  9. Sawyers
    Sawyers
  10. Solit
    Solit

Groups

  1. Department of Medicine (138)
  2. GSK Faculty (124)
  3. Hematologic Malignancies, Division of (71)
  4. Sloan Kettering Institute Faculty (71)
  5. Center for Hematologic Malignancies (69)
  6. Solid Tumor Oncology Division (69)
  7. Sloan Kettering Institute Postdocs (65)
  8. Human Oncology and Pathogenesis Program (59)
  9. Tow Center for Developmental Oncology (TCDO) (50)
  10. Department of Pathology and Laboratory Medicine (43)
Search Within
Formats
  1. Journal Article (207)
  2. Research Letter (12)
  3. Editorial (7)
  4. Review (6)
  5. Correspondence (5)
Groups
  1. Department of Medicine (138)
  2. GSK Faculty (124)
  3. Hematologic Malignancies, Division of (71)
  4. Sloan Kettering Institute Faculty (71)
  5. Center for Hematologic Malignancies (69)
  6. Solid Tumor Oncology Division (69)

More Groups

People
  1. Ross Levine (13)
  2. Michel Sadelain (11)
  3. Michael Berger (10)
  4. Omar Abdel-Wahab (9)
  5. Rona Yaeger (9)
  6. Elisa De Stanchina (8)

More People

Years
  1. 2025 (11)
  2. 2024 (23)
  3. 2023 (22)
  4. 2022 (17)
  5. 2021 (7)
  6. 2020 (15)

More Years

Publishers
  1. Nature Publishing Group (237)

Results (237)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • LILRB3 genetic variation is associated with kidney transplant failure in African American recipients
    Journal Article

    Sun, Z.; Yi, Z.; Wei, C.; Wang, W.; Ren, T.; Cravedi, P.; Tedla, F.; Ward, S. C.; Azeloglu, E.; Schrider, D. R.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: A randomized phase 3 trial
    Journal Article

    Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
    Journal Article

    Shitara, K.; Janjigian, Y. Y.; Ajani, J.; Moehler, M.; Yao, J.; Wang, X.; Chhibber, A.; Pandya, D.; Shen, L.; Garrido, M.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
    Journal Article

    Eskander, R. N.; Sill, M. W.; Beffa, L.; Moore, R. G.; Hope, J. M.; Musa, F. B.; Mannel, R. S.; Shahin, M. S.; Cantuaria, G. H.; Girda, E.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Symptom monitoring with electronic patient-reported outcomes during cancer treatment: Final results of the PRO-TECT cluster-randomized trial
    Journal Article

    Basch, E.; Schrag, D.; Jansen, J.; Henson, S.; Ginos, B.; Stover, A. M.; Carr, P.; Spears, P. A.; Jonsson, M.; Deal, A. M.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial
    Journal Article

    Usmani, S. Z.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Pour, L.; Martí, J. M.; Basu, S.; Cohen, Y. C.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: A randomized phase 3 trial
    Journal Article

    Kopetz, S.; Yoshino, T.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; Yaeger, R.; Maughan, T. S.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
    Journal Article

    Yoo, S. K.; Fitzgerald, C. W.; Cho, B. A.; Fitzgerald, B. G.; Han, C.; Koh, E. S.; Pandey, A.; Sfreddo, H.; Crowley, F.; Korostin, M. R.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
    Journal Article

    Raj, S. S.; Fei, T.; Fried, S.; Ip, A.; Fein, J. A.; Leslie, L. A.; Alarcon Tomas, A.; Leithner, D.; Peled, J. U.; Corona, M.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Democratizing precision oncology with SCORPIO
    Editorial

    Chowell, D.; Morris, L. G. T.
    Nature Medicine (2025)

    Fulltext@MSK | Save

    • Nature Medicine – authorized name for:

    Name ISSN / ISBN Publisher
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 10788956 2023, Crown
    Nature Medicine 10788956 2023, Springer Nature America, Inc
    Nature Medicine 1546-170X Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 10788956 2023, The Author(s)
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 10788956 2022, The Author(s), Under Exclusive Licence To Springer Nature America, Inc
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 10788956 2022, Springer Nature America, Inc
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 10788956 2021, Springer Nature America, Inc
    Nature Medicine 10788956 2021, The Author(s), Under Exclusive Licence To Springer Nature America, Inc
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 10788956 Unknown
    Nature Medicine 10788956 The Author(s) 2024
    Nature Medicine 10788956 2020, The Author(s), Under Exclusive Licence To Springer Nature America, Inc
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 10788956 2023, The Author(s), Under Exclusive Licence To Springer Nature America, Inc
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1546-170X Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature America, Inc
    Nature Medicine 10788956 2022, The Author(s)
    Nature Medicine 1078-8956 Nature America, Inc
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Publishing Group
    Nature Medicine 1078-8956 Nature Research
    Nature Medicine 10788956 2024, The Author(s), Under Exclusive Licence To Springer Nature America, Inc
    Nature Medicine 10788956 The Author(s) 2025